cardiology
Arrhythmia

Rivaroxaban gets approval for use in patients with renal impairment

Rivaroxaban (Xarelto) is now approved in Australia for patients with severe renal impairment down to a creatinine clearance of 15 mL/min. The change brings the DOACs use in Australia into line with other countries including in Europe, the US and Canada. Associate Professor Martin Gallagher, a nephrologist and program director of Acute Kidney Injury and ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic